AZD7442 – a potential combination therapy for the prevention and treatment of COVID-19

Study identifier:D8850C00001

ClinicalTrials.gov identifier:NCT04507256

EudraCT identifier:2020-003076-40

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults

Medical condition

COVID-19

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7442

Sex

All

Actual Enrollment

60

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 18 Aug 2020
Primary Completion Date: 19 Oct 2021
Study Completion Date: 19 Oct 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Parexel International

Inclusion and exclusion criteria